|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Paliperidone
gptkb:Invega
|
|
gptkbp:activities
|
dopamine D2 receptor antagonist
serotonin 5-H T2 A receptor antagonist
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1993
gptkb:United_States
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Risperdal_Consta
gptkb:Risperdal_M-TAB
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
|
|
gptkbp:contraindication
|
hypersensitivity to risperidone
severe CNS depression
|
|
gptkbp:developed_by
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
oral solution
long-acting injection
|
|
gptkbp:healthcare
|
gptkb:1993
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
risperidone
|
|
gptkbp:ingredients
|
C23 H27 F N2 O2 S
|
|
gptkbp:interacts_with
|
CNS depressants
antihypertensives
CY P2 D6 inhibitors
|
|
gptkbp:is_atype_of
|
N05 A X08
|
|
gptkbp:is_used_for
|
schizophrenia
bipolar disorder
irritability associated with autism
|
|
gptkbp:lifespan
|
20 hours
|
|
gptkbp:manager
|
oral
intramuscular
|
|
gptkbp:marketed_as
|
gptkb:Risperdal
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:population
|
gptkb:Person
adults
adolescents
|
|
gptkbp:previous_name
|
gptkb:risperidone
|
|
gptkbp:price
|
varies by country
|
|
gptkbp:side_effect
|
drowsiness
cardiovascular events
constipation
dry mouth
weight gain
hyperlipidemia
hyperglycemia
extrapyramidal symptoms
neuroleptic malignant syndrome
prolactin elevation
|
|
gptkbp:type_of
|
106266-06-2
|